Evotec SE Share Price

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 16:35:26 17/05/2024 BST 5-day change 1st Jan Change
9.76 EUR -4.97% Intraday chart for Evotec SE +2.52% -54.14%

Financials

Sales 2024 * 874M 950M 74.85B Sales 2025 * 1.04B 1.13B 88.84B Capitalization 1.73B 1.88B 148B
Net income 2024 * -29M -31.52M -2.48B Net income 2025 * 34M 36.95M 2.91B EV / Sales 2024 * 2.29 x
Net Debt 2024 * 269M 292M 23.03B Net Debt 2025 * 235M 255M 20.12B EV / Sales 2025 * 1.89 x
P/E ratio 2024 *
-58.8 x
P/E ratio 2025 *
30.9 x
Employees 5,061
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.97%
1 week+2.52%
Current month+0.21%
1 month-26.12%
3 months-28.58%
6 months-47.78%
Current year-54.14%
More quotes
1 week
9.50
Extreme 9.5
10.66
1 month
8.52
Extreme 8.52
14.22
Current year
8.52
Extreme 8.52
21.42
1 year
8.52
Extreme 8.52
24.44
3 years
8.52
Extreme 8.52
45.83
5 years
8.52
Extreme 8.52
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 18/06/19
Director of Finance/CFO 51 06/02/23
Chief Operating Officer 54 30/04/12
Members of the board TitleAgeSince
Chief Executive Officer 61 18/06/19
Director/Board Member 56 18/06/19
Chairman 63 16/06/14
More insiders
Date Price Change Volume
17/05/24 9.76 -4.97% 1,830,327
16/05/24 10.27 -2.00% 1,238,389
15/05/24 10.48 +2.04% 1,405,214
14/05/24 10.27 +3.01% 1,830,577
13/05/24 9.97 +4.73% 2,080,093

Delayed Quote Xetra, May 17, 2024 at 04:35 pm

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.76 EUR
Average target price
21.99 EUR
Spread / Average Target
+125.31%
Consensus